Dyadic International (DYAI) investor relations material

Company overview and business model

• Global biotechnology company with operations in the US and Netherlands, focused on precision-engineered, animal-free recombinant proteins and enzymes for life sciences, food, nutrition, and bio-industrial markets.

• Utilizes proprietary microbial expression platforms (C1 and Dapibus™) for scalable, cost-effective protein production.

• Engages third-party consultants, contract research organizations, and manufacturing partners for R&D and commercialization.

• Mission is to accelerate access to essential proteins through advanced biomanufacturing technologies.

Financial performance and metrics

• Classified as a "smaller reporting company" with market value of public float under $250 million or annual revenue under $100 million.

• Provides only two years of audited financials and management discussion due to reporting status.

Use of proceeds and capital allocation

• Will receive proceeds only from exercise of warrants, not from resale of shares by selling stockholders.

• Proceeds from warrant exercises intended for general corporate purposes, including R&D, sales and marketing, administrative expenses, working capital, capital expenditures, and potential acquisitions or strategic transactions.

• No current plans or commitments for acquisitions as of the filing date.